Cost-effectiveness of bivalent respiratory syncytial virus Prefusion F (RSVpreF) maternal vaccine among infants in the United StatesjeanfrancoismaisonMay 191 min readRated NaN out of 5 stars.https://pubmed.ncbi.nlm.nih.gov/40383082/
ANGPTL3: A Breakthrough Target in Treatment for Dyslipidemia and Atherosclerosishttps://pubmed.ncbi.nlm.nih.gov/40467521/
Targeting CD117 on hematopoietic stem and progenitor cells impairs CAR T cell activityhttps://pubmed.ncbi.nlm.nih.gov/40450523/
Comments